Preclinical analysis reveals IL-15 BCMA CAR-T cells improve antitumor activity in myeloma, implying enhanced efficacy over second generation CAR-Ts.
Key Points
IL-15 BCMA CAR-T cells demonstrated potent antitumor activity against myeloma in preclinical models, achieving significant tumor reduction.
Mean CAR+ frequency was 80.7% in 4th-generation BCMA CAR-T, indicating enhanced transduction efficiency compared to 2nd-generation CAR-T cells.
Assessment using co-culture assays confirmed robust antigen-specific cytotoxicity at various effector:target ratios, enhancing therapeutic implications.
Potential toxicity was noted with 4th-generation CAR-T cells, highlighting the need to balance efficacy and safety in CAR-T therapy.